Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

28-10-2015 | Gynecologic cancers | Article

Is It Time to Centralize Ovarian Cancer Care in the United States?

Journal: Annals of Surgical Oncology

Authors: Renee A. Cowan, MD, Roisin E. O’Cearbhaill, MD, Ginger J. Gardner, MD, Douglas A. Levine, MD, Kara Long Roche, MD, Yukio Sonoda, MD, Oliver Zivanovic, MD, William P. Tew, MD, Evis Sala, MD, PhD, Yulia Lakhman, MD, Hebert A. Vargas Alvarez, MD, Debra M. Sarasohn, MD, Svetlana Mironov, MD, Nadeem R. Abu-Rustum, MD, Dennis S. Chi, MD

Publisher: Springer International Publishing

Login to get access

Abstract

Purpose

The purpose of this article was to broadly review the most up-to-date information pertaining to the centralization of ovarian cancer care in the United States (US) and worldwide.

Methods

Much of the present literature pertaining to disparities in, and centralization of, ovarian cancer care in the US and internationally was reviewed, and specifically included original research and review articles.

Results

Data show improved optimal debulking rates, National Comprehensive Cancer Network (NCCN) guideline adherence, and overall survival rates in higher-volume, more specialized hospitals, and amongst higher-volume providers.

Conclusions

Patients with invasive epithelial ovarian cancer, especially those with higher stages (III and IV), are better served by centralized care in high-volume hospitals and by high-volume physicians, who adhere to NCCN guidelines wherever possible. More research is needed to determine the policy changes that can increase NCCN guideline adherence in low-volume hospitals and low-provider caseload scenarios. Policy and future research should be aimed at increasing patient access, either directly or indirectly, to high-volume hospital and high-volume providers, especially amongst Medicare, lower socioeconomic status, and minority patients.
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer Clin. 2015;65:5–29.CrossRef
2.
Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol. 2010;118:262–7.CrossRefPubMed
3.
Hoskins W, Rice L, Rubin S. Ovarian cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines. Oncology (Williston Park). 1997;11:896–900.PubMed
4.
Reade C, Elit L. Trends in gynecologic cancer care in North America. Obstet Gynecol Clin N Am. 2012;39:107–29.CrossRef
5.
Vernooij F, Heintz AP, Coebergh JW, Massuger LF, Witteveen PO, van der Graaf Y. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecol Oncol. 2009;112:455–61.CrossRefPubMed
6.
National Cancer Institute. NCI-designated cancer centers. http://​www.​cancer.​gov/​research/​nci-role/​cancer-centers (2015). Accessed 21 July 2015.
7.
Shalowitz DI, Vinograd AM, Giuntoli RL 2nd. Geographic access to gynecologic cancer care in the United States. Gynecol Oncol. 2015;138:115–20.CrossRefPubMed
8.
Wright JD, Herzog TJ, Siddiq Z, et al. Failure to rescue as a source of variation in hospital mortality for ovarian cancer. J Clin Oncol. 2012;30:3976–82.CrossRefPubMed
9.
Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California. Am J Obstet Gynecol. 2015;212:468.e1–9.
10.
Cliby WA, Powell MA, Al-Hammadi N, et al. Ovarian cancer in the United States: contemporary patterns of care associated with improved survival. Gynecol Oncol. 2015;136:11–7.CrossRefPubMed
11.
Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. 2014;132:403–10.CrossRefPubMed
12.
Mercado C, Zingmond D, Karlan BY, et al. Quality of care in advanced ovarian cancer: the importance of provider specialty. Gynecol Oncol. 2010;117:18–22.CrossRefPubMed
13.
Bristow RE, Chang J, Ziogas A, Campos B, Chavez LR, Anton-Culver H. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival. J Am Coll Surg. 2015;220:940–50.CrossRefPubMedPubMedCentral
14.
Ioka A, Tsukuma H, Ajiki W, Oshima A. Influence of hospital procedure volume on ovarian cancer survival in Japan, a country with low incidence of ovarian cancer. Cancer Sci. 2004;95:233–7.CrossRefPubMed
15.
Doufekas K, Olaitan A. Clinical epidemiology of epithelial ovarian cancer in the UK. Int J Womens Health. 2014;6:537–45.PubMedPubMedCentral
16.
Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancers: a Cochrane systematic review. Gynecol Oncol. 2012;126:286–90.CrossRefPubMed
17.
Kumpulainen S, Kuoppala T, Leminen A, et al. Surgical treatment of ovarian cancer in different hospital categories: a prospective nation-wide study in Finland. Eur J Cancer. 2006;42:388–95.CrossRefPubMed
18.
Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16 Suppl. 1:11–7.CrossRefPubMed
19.
Bristow RE, Chang J, Ziogas A, Anton-Culver H, Vieira VM. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol. 2014;134:60–7.CrossRefPubMedPubMedCentral
20.
Von Meyenfeldt EM, Gooiker GA, van Gijn W, et al. The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol. 2012;7:1170–8.CrossRef
21.
Wouters MW, Karim-Kos HE, le Cessie S, et al. Centralization of esophageal cancer surgery: does it improve clinical outcome? Ann Surg Oncol. 2009;16:1789–98.CrossRefPubMedPubMedCentral
22.
Singla A, Broadbridge V, Mittinty M, Beeke C, Maddern GJ. Rural populations have equal surgical and survival outcomes in metastatic colorectal cancer. Aust J Rural Health. 2014; 22:249–56.CrossRefPubMed
23.
Lemmens VE, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JW, de Hingh IH. Improving outcome for patients with pancreatic cancer through centralization. Br J Surg. 2011;98:1455–62.CrossRefPubMed
24.
Joudi FN, Konety BR. The impact of provider volume on outcomes from urological cancer therapy. J Urol. 2005;174:432–8.CrossRefPubMed
25.
Zivanovic O, Aldini A, Carlson JW, Chi DS. Advanced cytoreductive surgery: American perspective. Gynecol Oncol. 2009;114 (2 Suppl.):S3–S9.CrossRefPubMed
26.
Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. Epithelial ovarian cancer. J Natl Compr Cancer Netw. 2011;9:82–113.CrossRef
27.
Phippen NT, Barnett JC, Lowery WJ, Miller CR, Leath CA 3rd. Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility. Gynecol Oncol. 2013;131:158–62.CrossRefPubMed
28.
Bristow RE, Chang J, Ziogas A, Anton-Culver H. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol. 2013;121:1226–34.CrossRefPubMed
29.
Bristow RE, Santillan A, Diaz-Montes TP, et al. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer. 2007;109:1513–22.CrossRefPubMed
30.
Greving JP, Vernooij F, Heintz AP, van der Graaf Y, Buskens E. Is centralization of ovarian cancer care warranted? A cost-effectiveness analysis. Gynecol Oncol. 2009;113:68–74.CrossRefPubMed
31.
Aune G, Torp SH, Syversen U, Hagen B, Tingulstad S. Ten years’ experience with centralized surgery of ovarian cancer in one health region in Norway. Int J Gynecol Cancer. 2012;22:226–31.CrossRefPubMed
32.
Wright AA, Cronin A, Milne DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2015;33:2841–7.CrossRefPubMedPubMedCentral
33.
Lakhman Y, D'Anastasi M, Miccò M, et al. Second-opinion interpretations of gynecologic oncologic MRIExaminations by sub-specialized radiologists influence patient care. Eur Radiol. 2015. doi:10.​1007/​s00330-015-4040-5 CrossRefPubMedPubMedCentral